• Clinical Case Snapshot - Defining Risk in MDS
  • Current and Emerging Treatments for Myelodysplastic Syndromes
  • How I Approach MDS Diagnosis and Risk Assessment
  • Treatment Options for Low- and High-Risk Patients Based on the Prognostic Information Obtained
  • The Practice Essentials in MDS Series
  • Accredited e-Newsletter Series
  • MediCom Oncology Clinical Pearls Podcasts
  • Visit Our FAQ Library Now!
  • 5 Top Facts in MDS

What's New

5 Facts in MDS
Myelodysplastic Syndromes (MDS) are a rare group of bone marrow failure disorders
More...
CE Education
Current and Emerging Treatments for Myelodysplastic Syndromes
Mikkael A. Sekeres, MD, MS, and Amy E. DeZern, MD, MHS
CE Education
Current and Future Perspectives in the Treatment of High-risk MDS
Richard Stone, MD
Newsletters
Treatment Options for Low- and High-Risk Patients Based on the Prognostic Information Obtained
Hetty E. Carraway, MD, MBA, FACP
Clinical Case Snapshots
Defining Risk in MDS
Guillermo Garcia-Manero, MD
Clinical Commentaries
Experts Discuss DACOTA Phase 3 Trial of Decitabine versus Hydroxyurea for Advanced Proliferative CMML
Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD
CE Education
How I Approach MDS Diagnosis and Risk Assessment
Hetty E. Carraway, MD, MBA, FACP
Frequently Asked Questions
What is the clinical significance of SF3B1 in MDS and what are the key points I need to be aware of to determine treatment and outcome of these patients?
Rami S. Komrokji, MD